Cytosolix develops novel oral and IV derivatives that target tumor acidity to improve the efficacy of small molecule cancer therapeutics. Cytosolix's Tumor Activated Permeability System, produces weakly-acidic derivatives of known oncology drugs, that enhance the uptake by cancer cells while restricting the uptake by healthy cells, enabling physicians to get safer and more effective therapy for drugs with dose-limiting toxicities.

Tolland, CT, USA

Cytosolix

Bioscience

Medical device

Connecticut Innovations provides strategic capital and operational insight to push the frontiers of high-tech industries such as energy, biotechnology, information technology, and photonics. Over the years, CI has helped over 100 emerging companies research, develop, and market new products and services. This activity has attracted over $1 billion dollars in additional investments from private equity providers. CI has brought the State of Connecticut over $510 million in Gross State Profit and over 5,000 additional job-years.

Career Opportunities